Exploring the Utility of Whole-Genome Sequencing for the Diagnosis and Management of White Matter Disorders**

Sponsored By: Illumina

Date/Time: Monday, October 18, 2021 - 7:45 PM – 8:45 PM
Log in to Add to My Schedule

Description:

This session will provide an overview of the current state of WGS and transcriptomics for neurological disorders and discuss the impact results can have on clinical management and long-term outcomes. The presenters will review interim data from an observational study that implemented WGS as a first-tier test in patients with leukodystrophy and provide an overview of the next phase of that study which will evaluate clinical utility up to six months after results.

 

Speakers:

  • Kayla J. Muirhead, MS, LCGC; Children’s Hospital of Philadelphia
  • Holly Snyder, MS, LCGC; Illumina, Inc.
  • Ryan Taft, PhD; Illumina, Inc.